Abstract: There are systems and methods for preparing or using prognostic information about opioid response. The information may include determining patient information, including DNA information, associated with a human subject; determining from the DNA information whether a subject genotype of the human subject includes one or more SNP diploid polymorphisms by detecting, utilizing a detection technology and the DNA information, a presence or absence of the one or more SNP diploid polymorphisms in the subject genotype, wherein each SNP diploid polymorphism of the one or more SNP diploid polymorphisms includes a combination of two SNP alleles associated with one SNP location; and determining an opioid response associated with the human subject based, at least in part, on the presence or absence of the one or more SNP diploid polymorphisms in the subject genotype.

Abstract: There are systems and methods for preparing or using prognostic information about drug metabolism response. The information may include determining patient information, including DNA information, associated with a human subject; determining from the DNA information whether a subject genotype of the human subject includes one or more alleles or haplotypes in the one or more genes of the subject genotype by detecting, utilizing a detection technology and the DNA information, a presence or absence of the one or more alleles or haplotypes.

Abstract: There are systems and methods for preparing or using prognostic information about opioid maintenance response. The information may include determining patient information, including DNA information, associated with a human subject; determining from the DNA information whether a subject genotype of the human subject includes one or more SNP diploid polymorphisms by detecting, utilizing a detection technology and the DNA information, a presence or absence of the one or more SNP diploid polymorphisms in the subject genotype, wherein each SNP diploid polymorphism of the one or more SNP diploid polymorphisms includes a combination of two SNP alleles associated with one SNP location; and determining an opioid maintenance response associated with the human subject based, at least in part, on the presence or absence of the one or more SNP diploid polymorphisms in the subject genotype.

Abstract: There are systems and methods for preparing or using prognostic information about NSAID mediated side effect risks. The information may include determining patient information, including DNA information, associated with a human subject; determining from the DNA information whether a subject genotype of the human subject includes one or more SNP diploid polymorphisms by detecting, utilizing a detection technology and the DNA information, a presence or absence of the one or more SNP diploid polymorphisms in the subject genotype, wherein each SNP diploid polymorphism of the one or more SNP diploid polymorphisms includes a combination of two SNP alleles associated with one SNP location; and determining a NSAID mediated side effect risk associated with the human subject based, at least in part, on the presence or absence of the one or more SNP diploid polymorphisms in the subject genotype.

Abstract: There are systems and methods for preparing or using prognostic information about non-opioid response. The information may include determining patient information, including DNA information, associated with a human subject; determining from the DNA information whether a subject genotype of the human subject includes one or more SNP diploid polymorphisms by detecting, utilizing a detection technology and the DNA information, a presence or absence of the one or more SNP diploid polymorphisms in the subject genotype, wherein each SNP diploid polymorphism of the one or more SNP diploid polymorphisms includes a combination of two SNP alleles associated with one SNP location; and determining a non-opioid response associated with the human subject based, at least in part, on the presence or absence of the one or more SNP diploid polymorphisms in the subject genotype.

Abstract: There are methods, apparati and computer readable mediums associated with determining patient information, including DNA information, and determining from the DNA information whether a subject genotype of a human subject includes one or more SNP diploid polymorphisms by detecting, utilizing a detection technology and the DNA information, a presence or absence of the one or more SNP diploid polymorphisms in the subject genotype. The SNP diploid polymorphisms are selected from a SNP diploid group and utilized in determining an opioid dependency risk associated with the human subject.

Abstract: There are systems and methods for preparing or using prognostic information about pain perception or performing an assay based on such information. The information may include whether subject has a subject genotype that includes a COMT haplotype diploid, at least two SNP diploids, one or more demographic phenotypes or a combination thereof. The COMT haplotype diploid is a combination of two COMT haplotypes selected from an LPS haplotype, an APS haplotype, a HPS haplotype or a combination thereof in the COMT gene. The at least two SNP diploids are each a combination of two SNP alleles associated with one SNP location in the DRD1 gene, the COMT gene, the OPRK1 gene, the DRD2 gene, the MTHFR gene, the SLC6A4 gene, the HTR2A gene, the DBH gene, the GABRG2 gene, the OPRM1 gene or the SLC6A3 gene.

Abstract: There is a system and a method for performing medical research. The method includes receiving a registration record. The registration record is for documenting a participant's involvement in a clinical trial. The method may also include receiving an evaluation record for documenting biological information associated with the participant in the clinical trial. The method may also include generating a payment record. The payment record may include a payment value associated with the evaluation record. The registration record may include a service authorization. The service authorization may be for a service the participant receives for collecting the biological information.

Abstract: There are systems and methods for performing an assay to generate genotype information about a subject associated with a medical condition. There are also systems and method for generating and utilizing prognostic information associated with treating the patient with a medication based on the genotype information and an association of the genotype and metabolizing the medication. The genotype information includes data relating to SNP alleles in the patient's genotype and the association of the alleles and metabolism of a medication by the patient.

Abstract: There are systems and methods for performing an assay to generate genotype information about a subject associated with a chronic pain condition. There are also systems and method for generating and utilizing prognostic information associated with treating the patient with a pain medication based on the genotype information. The genotype information includes data relating to specific SNP alleles in the patient's genotype.

Abstract: The present invention provides a method of effectively measuring risk for therapeutic toxicity of a subject having an autoimmune disorder or cancer and predicting and evaluating therapeutic efficacy of immunosuppressive therapies for autoimmune diseases and cancers before or after starting therapy. The present invention also provides for determining a drug metabolite level of a subject during therapy and measuring periodically the drug metabolite level of a subject on maintenance therapy to ensure treatment compliance and continued therapeutic response by measuring minimal clinical important differences (MCID) in the drug metabolite levels.

Abstract: The present invention relates to a composition and custom business model and methods to measure genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients, and other ingredients for the purposes of customizing a subject's nutritional supplements with custom formulations to optimize health outcomes.